168 related articles for article (PubMed ID: 33622598)
1. Evaluation of the significance of pseudomyxoma peritonei patients based on the Peritoneal Surface Oncology Group International (PSOGI) classification.
Lee JL; Kim M; Kim J; Kim CW; Ha YJ; Kim SY; Cho DH; Kim JC
Asian J Surg; 2021 Jun; 44(6):848-853. PubMed ID: 33622598
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
3. External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification.
Arjona-Sanchez A; Martinez-López A; Moreno-Montilla MT; Mulsow J; Lozano-Lominchar P; Martínez-Torres B; Rau B; Canbay E; Sommariva A; Milione M; Deraco M; Sgarbura O; Torgunrud A; Kepenekian V; Carr NJ; Hoorens A; Delhorme JB; Wernert R; Goere D; Martin-Roman L; Cosyns S; Flatmark K; Davidson B; Khellaf L; Pereira-Perez F; Rodriguez-Ortiz L; Ibáñez-Costa A; Romero-Ruiz A;
Eur J Surg Oncol; 2023 Aug; 49(8):1481-1488. PubMed ID: 36935222
[TBL] [Abstract][Full Text] [Related]
4. From the Ronnett to the PSOGI Classification System for Pseudomyxoma Peritonei: A Validation Study.
Rufián-Andujar B; Valenzuela-Molina F; Rufián-Peña S; Casado-Adam Á; Sánchez-Hidalgo JM; Rodríguez-Ortiz L; Medina-Fernández FJ; Díaz-López C; Ortega-Salas R; Martínez-López A; Briceño-Delgado J; Romero-Ruíz A; Arjona-Sánchez Á
Ann Surg Oncol; 2021 May; 28(5):2819-2827. PubMed ID: 33471266
[TBL] [Abstract][Full Text] [Related]
5. A Proposal for Modification of the PSOGI Classification According to the Ki-67 Proliferation Index in Pseudomyxoma Peritonei.
Arjona-Sánchez Á; Martínez-López A; Valenzuela-Molina F; Rufián-Andújar B; Rufián-Peña S; Casado-Adam Á; Sánchez-Hidalgo JM; Rodríguez-Ortiz L; Medina-Fernández FJ; Díaz-López C; Granados-Rodríguez M; Ortega-Salas R; Castaño JP; Tena-Sempere M; Briceño-Delgado J; Romero-Ruíz A
Ann Surg Oncol; 2022 Jan; 29(1):126-136. PubMed ID: 34215955
[TBL] [Abstract][Full Text] [Related]
6. Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes.
Baratti D; Milito P; Kusamura S; Martin Roman L; Guaglio M; Deraco M
Eur J Surg Oncol; 2022 Jul; 48(7):1590-1597. PubMed ID: 35090796
[TBL] [Abstract][Full Text] [Related]
7. Can low grade PMP be divided into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification.
Bhatt A; Mishra S; Prabhu R; Ramaswamy V; George A; Bhandare S; Shah M; Mehta S
Eur J Surg Oncol; 2018 Jul; 44(7):1105-1111. PubMed ID: 29685759
[TBL] [Abstract][Full Text] [Related]
8. Correlation between PSOGI pathological classification and survival outcomes of patients with pseudomyxoma peritonei treated using cytoreductive surgery and HIPEC: national referral centre experience and literature review.
Martín-Román L; Hannan E; Faraz Khan M; Müller AS; Shields C; Aird J; Moran B; Mulsow J
Pleura Peritoneum; 2023 Jun; 8(2):65-74. PubMed ID: 37304162
[TBL] [Abstract][Full Text] [Related]
9. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei.
Hotta M; Minamimoto R; Gohda Y; Igari T; Yano H
Eur Radiol; 2019 Oct; 29(10):5709-5716. PubMed ID: 30874878
[TBL] [Abstract][Full Text] [Related]
10. Pseudomyxoma peritonei (PMP) and its therapy - 20 years experience of a single surgical department.
Bartoška P; Antoš F; Vítek P; Marx J; Holečková P; Novotný M; Kengbaeva M
Rozhl Chir; 2020; 99(4):159-166. PubMed ID: 32545978
[TBL] [Abstract][Full Text] [Related]
11. Which classification system defines best prognosis of mucinous neoplasms of the appendix with peritoneal dissemination: TNM vs PSOGI?
Martín-Román L; Lozano P; Gómez Y; Fernández-Aceñero MJ; Vasquez W; Palencia N; González-Bayón L
J Clin Pathol; 2023 Apr; 76(4):266-273. PubMed ID: 34725195
[TBL] [Abstract][Full Text] [Related]
12. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process.
Carr NJ; Cecil TD; Mohamed F; Sobin LH; Sugarbaker PH; González-Moreno S; Taflampas P; Chapman S; Moran BJ;
Am J Surg Pathol; 2016 Jan; 40(1):14-26. PubMed ID: 26492181
[TBL] [Abstract][Full Text] [Related]
13. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
[No Abstract] [Full Text] [Related]
14. Combined ultrasonography and CT for prognosis and predicting clinical outcomes of patients with pseudomyxoma peritonei.
Han X; Zhang Q; Zhou N; Ma R; Wang J; Zhai X; Cui B; Lu Y; Liang L
Eur Radiol; 2023 Apr; 33(4):2800-2808. PubMed ID: 36418618
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
[TBL] [Abstract][Full Text] [Related]
16. Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Horvath P; Yurttas C; Birk P; Struller F; Königsrainer A
Langenbecks Arch Surg; 2018 Dec; 403(8):985-990. PubMed ID: 30506401
[TBL] [Abstract][Full Text] [Related]
17. Pseudomyxoma peritonei: visceral scalloping on CT is a predictor of recurrence after complete cytoreductive surgery.
Hotta M; Minamimoto R; Gohda Y; Tajima T; Kiyomatsu T; Yano H
Eur Radiol; 2020 Aug; 30(8):4193-4200. PubMed ID: 32211961
[TBL] [Abstract][Full Text] [Related]
18. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment.
Govaerts K; Lurvink RJ; De Hingh IHJT; Van der Speeten K; Villeneuve L; Kusamura S; Kepenekian V; Deraco M; Glehen O; Moran BJ;
Eur J Surg Oncol; 2021 Jan; 47(1):11-35. PubMed ID: 32199769
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
Lu YY; Guo AT; Liu AJ; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
[TBL] [Abstract][Full Text] [Related]
20. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
